HOME >> MEDICINE >> NEWS
JCI table of contents, 1 August 2003

https://www.the-jci.org/press/17864.pdf


Increasing tolerance to contact allergens

Common contact allergies are triggered by allergens that affect the skin such as poison oak, poisin ivy, latex, dyes, fragrances, and metals. Researchers at the University of Mainz, Germany, have now shown that IL-10, a critical mediator of the immune response, is required in order to build-up tolerance to such allergens. The authors achieve what is known as low zone tolerance (LZT), in which repeated applications of low doses of contact allergens hinders the development of the allergic reaction. They demonstrate that mice lacking IL-10 cannot achieve LZT to allergens, suggesting that this IL-10driven response may be utilized in allergic therapies.

TITLE: Critical role of IL-10 in the induction of low zone tolerance to contact allergens

AUTHOR CONTACT:
Kerstin Steinbrink
University of Mainz, Mainz, Germany.
Phone: 49-6131-17-2297
Fax: 49-6131-17-6614
E-mail: steinbrink@hautklinik.klinik.uni-mainz.de

View the PDF of this article at: https://www.the-jci.org/press/18106.pdf


OutFoxing obesity

Obesity results from a massive expansion of fat cells. This expansion involves the differentiation of early precursor fat cells, known as preadipocytes, into mature fat cells. Researchers at Rockefeller University in New York have revealed that preadipocytes stably expressing the Foxa-2 protein do not differentiate into mature fat cells. Furthermore, in multiple rodent models of obesity they observed that Foxa-2 production is increased, in what may be an important counterregulatory mechanism to prevent the expansion of fat cell numbers. While the stimuli that induce Foxa-2 expression in mature fat cells is unknown, the authors propose that the pathways inv
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
1-Aug-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Portable system offers dialysis patients liberating changes
2. Milk, fruits and vegetables may help reduce disability risk
3. Parents comfortable with vaccination for sexually transmitted infections for adolescent children
4. JCI table of contents, January 20 2005
5. Most adverse events in hospitalized children are preventable
6. Study finds no reduction in breast cancer risk with consumption of vegetables and fruits
7. Requip tablets treat symptoms of primary RLS
8. Medical negligence system is secretive, unaccountable and unregulated
9. Spina bifida: 70% of cases preventable by folic-acid supplementation
10. Determining which pancreatic cancers are treatable
11. Vegetable lovers should be viewed as different from fruit aficionados

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents August

(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... According to ... been developed that changes color when subjected to an impact force that is great ... be implemented in helmets or other sporting equipment so that coaches or officials would ...
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article published August ... Association presented data showing that it is safe for pregnant women to undergo local ... had undergone local anesthesia with a group that hadn’t, researchers were able to determine ...
(Date:9/4/2015)... ... September 04, 2015 , ... On ... has effectively doubled the size of its annual health tech innovation program. Now ... digital health startups to compete for cash and prizes to advance their technologies ...
(Date:9/4/2015)... , ... September 04, 2015 , ... With TransCel from ... mouse all within Final Cut Pro X. With TransCel users have full control over ... width, background color, speed method, frame color, inner color, text, and more. With TransCel ...
(Date:9/4/2015)... ... 2015 , ... Mile High Connects today releases “First and Last Mile Connections,” ... sidewalks, bike paths, and other vital supports severely limit access to public transportation for ... dollars to expand public transit, there’s very little support for safe and convenient access ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:Missed Connections in Metro Denver Transit 2
(Date:9/4/2015)... , Sept. 4, 2015  Janssen Research & ... and Drug Administration (FDA) has accepted for Priority ... as a treatment for patients with multiple myeloma ... (PI) and an immunomodulatory agent (IMiD), or who ... therapy, including a PI and an IMiD. This ...
(Date:9/4/2015)... -- Fair Rate Funding, a lawsuit funding firm located in ... increase in lawsuit filings in connection with the blood thinning ... Philadelphia Court of Common Pleas has ... Louisiana multi---district litigation (MDL), located in ... Louisiana , the filings are also on the ...
(Date:9/4/2015)... HILL, N.C. , Sept. 4, 2015 /PRNewswire/ ... Liaisons (MSLs) and other Field-Based Medical Specialists (FBMS) ... key opinion leaders, and thought leaders in critical ... effectiveness of their field-based teams, companies are expanding ... order to align countries with corporate objectives and ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2
Cached News: